Alnylam Pharma’s Growth Potential: Buy Rating Backed by Strong Sales and Future Projections

Joseph Stringer, an analyst from Needham, maintained the Buy rating on Alnylam Pharma (ALNY – Research Report). The associated price target remains the same with $320.00.

Joseph Stringer has given his Buy rating due to a combination of factors including Alnylam Pharma’s reported product sales and future projections. Although the company’s first-quarter sales of $469 million were slightly below his expectations, they aligned with market consensus, showing a 28% year-over-year increase.
Another key factor in his positive outlook is the ongoing launch of Amvuttra for ATTR-CM, which is anticipated to be a significant growth driver for the company in 2025. Additionally, the company’s guidance for total product sales in 2025 remains strong, and there is an expectation of achieving sustainable non-GAAP profitability by that time.